Maa: Kanada
Kieli: englanti
Lähde: Health Canada
AZITHROMYCIN (AZITHROMYCIN DIHYDRATE)
MANTRA PHARMA INC
J01FA10
AZITHROMYCIN
250MG
TABLET
AZITHROMYCIN (AZITHROMYCIN DIHYDRATE) 250MG
ORAL
15G/50G
Prescription
OTHER MACROLIDES
Active ingredient group (AIG) number: 0126072001; AHFS:
APPROVED
2020-07-28
PRODUCT MONOGRAPH Pr M-AZITHROMYCIN Azithromycin Dihydrate Tablets 250 mg and 600 mg Azithromycin (supplied as azithromycin dihydrate), manufacturer’s standard Antibacterial Agent Mantra Pharma Inc. Date of Revision: 9150 Leduc BLVD, Suite 201, Brossard July 24, 2020 Quebec, Canada J4Y 0E3 Control Submission #: 240728 Pr M-Azithromycin (as azithromycin dihydrate) Product Monograph Page 2 of 62 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ............................................................................. 3 SUMMARY PRODUCT INFORMATION .............................................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................................... 3 CONTRAINDICATIONS ......................................................................................................................... 4 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ......................................................................................................................... 8 DRUG INTERACTIONS ....................................................................................................................... 14 DOSAGE AND ADMINISTRATION ................................................................................................... 19 OVERDOSAGE ...................................................................................................................................... 20 ACTION AND CLINICAL PHARMACOLOGY .................................................................................. 20 STORAGE AND STABILITY ............................................................................................................... 23 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................................................... 23 PART II: SCIENTIFIC INFORMATION ...................... Lue koko asiakirja